Mangoceuticals Unveils Groundbreaking MGX-0024 Results
In exciting developments from the health and wellness sector, Mangoceuticals, Inc. (NASDAQ: MGRX) has reported impressive results regarding their patented antiviral compound, MGX-0024. This innovative solution demonstrates incredible potential for the poultry industry, especially concerning respiratory diseases that threaten chicken populations globally.
Promising Results from Field Studies
The company conducted extensive trials at Duraiswamy Farm in India, focusing on respiratory health in chickens. These studies have yielded remarkable findings, with MGX-0024 achieving 100% survival in flocks affected by respiratory illnesses. In comparison to untreated neighboring farms, the efficacy of this solution marks a significant breakthrough in poultry health.
First Study Insights
During the first major study, more than 8,000 birds were given MGX-0024 through their drinking water. The outcomes were striking; mortality rates from respiratory diseases were drastically lower, with only about 50 deaths per day compared to over 200 on a nearby untreated farm. The study highlighted that some fatalities could have stemmed from pre-existing infections, emphasizing the urgent need for effective antiviral solutions in poultry farming.
Second Study Findings
In a second study involving 10,000 chicks introduced to MGX-0024 at just 7 days old, the results were even more favorable. Over 48 days, the treated group reported zero deaths related to respiratory infections. The control group, in contrast, faced severe mortality with an expected death rate suggesting 50% loss due to untreated respiratory issues.
Addressing Global Health Concerns
Ultimately, this research supports the notion that MGX-0024 could offer a drug-free, vaccine-free alternative to protect poultry from respiratory diseases, a crucial consideration given recent global trends in reducing antibiotic use. With India planning a ban on antibiotic growth promoters starting in April 2025, Mangoceuticals is ahead of the curve, positioning itself as a leader in the pursuit of antibiotic-free poultry production.
Strategic Market Engagement
Mangoceuticals is also taking significant steps to launch MGX-0024 to the market rapidly. The company is scaling production efforts and has begun discussions with large commercial farms across the US, UK, Canada, and Australia. Their proactive engagement with regulatory authorities signifies a strategic move towards ensuring that MGX-0024 becomes a recognized front-line defense against both respiratory diseases and zoonotic threats like avian flu.
Future Development and Partnerships
As part of ongoing research, further studies are planned at Duraiswamy Farm, along with other farms in regions with known H5N1 activities. This will ensure that MGX-0024’s effectiveness is validated comprehensively. Additionally, MangoRx IP Holdings, LLC, the company's subsidiary owning the patent for MGX-0024, is actively seeking federal funding to support the broader rollout of this promising solution.
Feedback from Leadership
Jacob Cohen, the Co-Founder and CEO of Mangoceuticals, emphasized the potential for MGX-0024 to stabilize farm production: “We’re focused on making MGX-0024 a standard in poultry health. Our solution meets the need for safe, alternative treatment methods while aligning with current health policies aimed at reducing antibiotic reliance.”
Contact Information and Engagement
For further insights into Mangoceuticals’ ongoing projects or MGX-0024, you can reach out to their investor relations team at investors@mangorx.com or visit www.mangorxipholdings.com.
Frequently Asked Questions
What is MGX-0024?
MGX-0024 is a patented antiviral compound developed by Mangoceuticals aimed at preventing respiratory diseases in poultry.
How effective is MGX-0024 in trials?
Trials have shown MGX-0024 to achieve 100% respiratory survival rates in chickens, significantly reducing mortality compared to untreated groups.
What are the global implications of MGX-0024?
This compound aligns with global health regulations aiming to reduce antibiotic use, offering a natural solution for poultry health.
Where are the studies conducted?
The studies were conducted at Duraiswamy Farm in Tamil Nadu, India, with plans for further trials at additional sites.
How can I learn more about Mangoceuticals?
For more details, you can visit their website or contact their investor relations team via email.
